← Leaderboards
Allison M Dubner
University Of Colorado Denver
$86,380
Attributed
$86,380
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $34.8K · FY2021–23$50K$37.5K$25K$12.5K$0
'21
'22
'23
Funding mix
By agency
NIH$86,380 · 1
By mechanism
F31$86,380 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Mary Cm Weiser-Evans$14,403,734
- Kurt R Stenmark$22,132,904
- Mark Robert Nicolls$22,256,364
- Heide L Ford$14,422,349
- Thomas E Morrison$8,729,587
Others in their field
Other Emerging Leaders on “Acute”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$51,003,204
- Julie Ake · National Institute Of Allergy And Infectious Diseases$41,692,120
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$29,269,420
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
Research focus
AcuteFlow CytometryAtherosclerosisAutomobile DrivingFibrosisBeta CateninBlood VesselsCell Differentiation ProcessCellsCholesterolChronicArterial Fatty StreakComplexCoronary ArteryDefined ContributionDietDiphtheria Toxin ReceptorDisease ProgressionEndothelial CellsEndotheliumErinaceidaeFallsFatty Acid Glycerol EstersGene Expression
Grant awards (3)
Role of Smooth Muscle-derived Vascular Progenitor Cells (AdvSca1-SM) in Vasa Vasorum Expansion and Atherosclerotic Plaque Progression$17,586
F31 · FY2023 · HL · contact PI
Role of Smooth Muscle-derived Vascular Progenitor Cells (AdvSca1-SM) in Vasa Vasorum Expansion and Atherosclerotic Plaque Progression$34,755
F31 · FY2022 · HL · contact PI
Role of Smooth Muscle-derived Vascular Progenitor Cells (AdvSca1-SM) in Vasa Vasorum Expansion and Atherosclerotic Plaque Progression$34,039
F31 · FY2021 · HL · contact PI